

TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED
(Formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited)
(Company Registration No.: 91120000103100784F)
(Incorporated in the People's Republic of China)

RESULTS OF EXTRAORDINARY GENERAL MEETING HELD ON 15 DECEMBER 2025

The Board of Directors (the “**Board**”) of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (the “**Company**”) wishes to announce that at the Extraordinary General Meeting (“**EGM**”) of the Company held on 15 December 2025, all resolutions relating to the matters set out in the Notice of EGM dated 28 November 2025 (which superseded the Notice of EGM dated 30 October 2025) were duly passed.

The results of the poll on each of the resolutions put to vote at the EGM are set out below. All the resolutions were duly passed at the EGM.

No.	Resolutions relating to:	Total number of shares represented by votes for and against the relevant resolution	FOR		AGAINST		FORFEITED	
			Number of shares	As a percentage of total number of votes for and against the resolution (%)	Number of shares	As a percentage of total number of votes for and against the resolution (%)	Number of shares	As a percentage of total number of votes for and against the resolution (%)
1	To consider and approve the proposed amendments to the existing shareholders' mandate for interested person transactions	11384351	9163449	80.492	41100	0.361	2179802	19.147
2	To consider and approve the proposed purchase of the liability insurance for the Company and its directors, supervisors and senior management	11384351	11066549	97.208	177200	1.557	140602	1.235
3	To consider and approve the proposed amendments to the Articles of Association of the Company and the	337239879	337034677	99.939	52300	0.016	152902	0.045

No.	Resolutions relating to:	Total number of shares represented by votes for and against the relevant resolution	FOR		AGAINST		FORFEITED	
			Number of shares	As a percentage of total number of votes for and against the resolution (%)	Number of shares	As a percentage of total number of votes for and against the resolution (%)	Number of shares	As a percentage of total number of votes for and against the resolution (%)
	application for changes in the industrial and commercial registration							
4	To consider and approve the proposed re-appointment of CAC Certified Public Accountants LLP (中审华会计师事务所) as the PRC auditors of the Company for FY2025 to hold office until the conclusion of the next annual general meeting, and the proposed re-appointment of Foo Kon Tan LLP as the international auditors of the Company for FY2025 to hold office until the conclusion of the next annual general meeting, and to propose to Shareholders at the Extraordinary General Meeting to authorise the Board to determine their respective remuneration	337239879	337026177	99.937	37900	0.011	175802	0.052
5	To consider and approve the proposed	337239879	337137077	99.970	38900	0.012	63902	0.019

No.	Resolutions relating to:	Total number of shares represented by votes for and against the relevant resolution	FOR		AGAINST		FORFEITED	
			Number of shares	As a percentage of total number of votes for and against the resolution (%)	Number of shares	As a percentage of total number of votes for and against the resolution (%)	Number of shares	As a percentage of total number of votes for and against the resolution (%)
	declaration of an interim dividend for FY2025							

Details of parties who are required to abstain from voting on the resolution

The following director of the Company had abstained from voting on Resolution 2 in relation to the proposed purchase of the liability insurance for the Company and its directors, supervisors and senior management:

Name	Number of Shares Held
Zhou Hong	23,800 A-shares

Tianjin Pharmaceutical Holdings Co., Ltd. (“TPH”) (being the controlling shareholder of the Company), which holds 325,855,528 A-shares in the Company, and Jinyao Global Pte. Ltd. (formerly known as Tianjin Pharmaceutical (Singapore) International Investment Pte. Ltd.) (being the wholly-owned subsidiary of TPH), which holds 5,265,000 S-shares in the Company, had abstained from voting on Resolution 1 in relation to the proposed amendments to the existing shareholders’ mandate for interested person transactions and Resolution 2 in relation to the proposed purchase of the liability insurance for the Company and its directors, supervisors and senior management. Further, Jinhushen Biological Medical Science and Technology Co., Ltd (津沪深生物医药科技有限公司) (being the controlling shareholder of TPH), which holds 4,497 A-shares in the Company, had also abstained from voting on Resolutions 1 and 2. In addition, TPH and its associates did not accept nominations as proxies or otherwise for voting on Resolutions 1 and 2 at the EGM, unless they were given specific instructions by independent shareholder(s) as to how to vote.

Scrutineer

Pursuant to Rule 704(16) of the Listing Manual, Drewcorp Services Pte Ltd acted as the Company’s scrutineer for the EGM.

BY ORDER OF THE BOARD

Jiao Yan
Secretary to the Board of Directors
15 December 2025